MD : NYSE : Health Care
$42.27 | %
Today's Range: 41.53 - 42.44
Avg. Daily Volume: 936200.0
08/18/17 - 4:02 PM ET

Financial Analysis


MEDNAX INC's gross profit margin for the second quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. MEDNAX INC has strong liquidity. Currently, the Quick Ratio is 1.52 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has increased by 10.95% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)842.94771.76
EBITDA ($mil)147.64168.03
EBIT ($mil)121.9147.79
Net Income ($mil)63.782.43


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)51.5862.48
Total Assets ($mil)5407.44771.41
Total Debt ($mil)1773.171439.45
Equity ($mil)2838.252557.97


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin29.7433.71
EBITDA Margin17.5121.77
Operating Margin14.4619.15
Sales Turnover0.620.63
Return on Assets5.416.99
Return on Equity10.3213.04
Debt Q2 FY17 Q2 FY16
Current Ratio1.591.65
Debt/Capital0.380.36
Interest Expense18.5415.06
Interest Coverage6.589.81


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)93.4893.5
Div / share0.00.0
EPS0.690.89
Book value / share30.3627.36
Institutional Own % n/a n/a
Avg Daily Volume956390.0934046.0

Valuation


HOLD. MEDNAX INC's P/E ratio indicates a significant discount compared to an average of 24.74 for the Health Care Providers & Services industry and a significant discount compared to the S&P 500 average of 24.31. For additional comparison, its price-to-book ratio of 1.39 indicates a significant discount versus the S&P 500 average of 3.03 and a significant discount versus the industry average of 3.25. The current price-to-sales ratio is well below the S&P 500 average, but above the industry average. Upon assessment of these and other key valuation criteria, MEDNAX INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MD 13.32 Peers 24.74   MD 8.91 Peers 11.63

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

MD is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MD is trading at a discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MD 11.88 Peers 16.56   MD NM Peers 0.73

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

MD is trading at a discount to its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MD's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MD 1.39 Peers 3.25   MD -11.74 Peers 24.13

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MD is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, MD is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MD 1.18 Peers 0.90   MD 11.67 Peers 8.31

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MD is trading at a significant premium to its industry.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

MD has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades